脑梗死急性期阿托伐他汀极量强化治疗与康复预后关系的前瞻性研究

发布时间：2018-08-17 15:17

【摘要】：目的探讨脑梗死急性期阿托伐他汀极量80 mg·d~(-1)强化治疗对患者临床康复预后的影响。方法连续入组238例脑梗死患者,随机分入阿托伐他汀20 mg组和80 mg组各119例,每日分别给予相应剂量的阿托伐他汀口服治疗14 d,对患者神经功能残疾状况跟踪观察3个月,并以美国国立卫生研究院卒中量表(NIHSS)和改良Rankin评分(mRS)量表进行量化评价。结果根据随访3个月时的NIHSS评分,阿托伐他汀20 mg组有效38例,80 mg组有效54例,组间具有显著差异(P=0.033);随访3个月时80 mg组mRS评分显著低于20 mg组(P=0.012)。Logistic回归分析显示脑梗死急性期阿托伐他汀80 mg·d~(-1)强化治疗为康复预后的独立影响因素,OR值为1.961,95%可信区间1.139~3.376,P=0.015。结论脑梗死急性期应用阿托伐他汀80 mg·d~(-1)强化治疗对于改善患者康复预后具有更好的促进作用。
[Abstract]:Objective to investigate the effect of intensive treatment of Atto vastatin 80 mg d-1 on the prognosis of patients with acute cerebral infarction. Methods two hundred and eight consecutive patients with cerebral infarction were randomly divided into Atto vastatin 20 mg group (n = 119) and 80 mg group (n = 119). The patients were given corresponding doses of Atto vastatin orally for 14 days. The neurological disability was observed for 3 months. The stroke scale of the National Institutes of Health (NIHSS) and the modified Rankin scale (mRS) were used for quantitative evaluation. Results according to the NIHSS score of 3 months follow-up, 54 cases were effective in Atto 20 mg group (38 cases) and 80 mg group (54 cases). After 3 months follow-up, the mRS score of 80 mg group was significantly lower than that of 20 mg group (P0. 012). Logistic regression analysis showed that the independent influencing factor of intensive treatment of Atto vastatin 80 mg d ~ (-1) in acute cerebral infarction was 1.961- 95% confidence interval 1.1393.376P0.015. Conclusion intensive treatment with Atto vastatin 80mg d-1 in acute stage of cerebral infarction can improve the prognosis of patients with cerebral infarction.
【作者单位】：首都医科大学附属北京潞河医院神经内科;
【基金】：首都医科大学附属北京潞河医院临床科研能力提升工程基金北京市通州区科委科研基金(KJ2015CX004-11)
【分类号】：R743.33

【参考文献】